Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial by Monk, Bradley J, Prof, Poveda, Andrés, MD, Vergote, Ignace, MD, Raspagliesi, Francesco, MD, Fujiwara, Keiichi, MD, Bae, Duk-Soo, MD, Oaknin, Ana, MD, Ray-Coquard, Isabelle, MD, Provencher, Diane M, MD, Karlan, Beth Y, MD, Lhommé, Catherine, MD, Richardson, Gary, MD, Rincón, Dolores Gallardo, MD, Coleman, Robert L, MD, Herzog, Thomas J, MD, Marth, Christian, PhD, Brize, Arija, MD, Fabbro, Michel, MD, Redondo, Andrés, MD, Bamias, Aristotelis, PhD, Tassoudji, Marjan, MS, Navale, Lynn, MS, Warner, Douglas J, MD, Oza, Amit M, MD

Get full text